

1 **Major depressive disorder but not bipolar disorder and schizophrenia is a causal factor**  
2 **for type 2 diabetes as determined by Mendelian randomization**

3

4 **Short title: Psychiatric disorders and type 2 diabetes risk**

5

6 **Heejin Jin, M.S.<sup>1,2</sup>, Jeewon Lee, M.D., Ph.D.<sup>3</sup>, Sohee Oh, Ph.D.<sup>2</sup>, Sanghun Lee, Ph.D.<sup>4\*</sup>,**

7 **Sungho Won, Ph.D.<sup>1,5\*</sup>**

8 <sup>1</sup>Department of Public Health Science, Seoul National University, Seoul, Korea

9 <sup>2</sup>Medical Research Collaborating Center, Department of Biostatistics, Seoul National  
10 University Boramae Hospital, Seoul, Republic of Korea

11 <sup>3</sup>Department of Psychiatry, Soonchunhyang University Bucheon Hospital, Bucheon, Republic  
12 of Korea

13 <sup>4</sup>Department of Medical Consilience, Graduate School, Dankook University, Yongin-si,  
14 Republic of Korea

15 <sup>5</sup>Institute of Health and Environment, Seoul National University, Seoul, South Korea.

16

17 \* Correspondence:

18 Sungho Won, Department of Public Health Science, Seoul National University

19 1 Kwanak-ro Kwanak-gu Seoul 151-742 Korea

20 (Email) won1@snu.ac.kr, (Tel) +82-2-880-2714, (Fax) +82-303-0942-2714

21

22 Sanghun Lee, Department of Medical Consilience, Graduate School, Dankook University,

23 126-0 Suji-gu Yongin-si Gyeonggi-do Korea

24 (Email) sanghunlee73@gmail.com, (Tel) +82-10-2602-3759

25

26 Word count: 3,688

27 Number of tables and figures: 3 tables and 1 figure

28

29 **ABSTRACT**

30 Objective: In many epidemiologic studies, type 2 diabetes has been reported to be associated  
31 with severe mental illness (SMI) such as schizophrenia (SCZ), bipolar disorder (BPD), and  
32 major depressive disorder (MDD). However, the relationship between SMI and type 2 diabetes  
33 is bi-directional, and the causal relationship remains unclear due to various confounders.  
34 Therefore, a Mendelian randomization (MR) study is necessary to identify the causality  
35 between them.

36 Research Design and Methods: We conducted a two-sample MR study to identify the causal  
37 effect of SMI on type 2 diabetes using the inverse-variance weighted (IVW), MR-Egger, MR-  
38 Egger with a simulation extrapolation, weighted median approach, and MR-Pleiotropy  
39 RESidual Sum and Outlier methods. The most appropriate method was selected according to  
40 the instrument variables assumption.

41 Results: We found that MDD had a significant causal effect on type 2 diabetes from the results  
42 obtained using the IVW method (Odds ratio (OR): 1.191, 95% CI: 1.036–1.372,  $P = 0.014$ );  
43 however, this was not observed for BPD (IVW, OR: 1.006, 95% CI: 0.918–1.104,  $P = 0.892$ )  
44 or SCZ (IVW, OR: 1.016, 95% CI: 0.974–1.059,  $P = 0.463$ ). The absence of reverse-causality  
45 between MDD and type 2 diabetes was also demonstrated from bi-directional MR studies.

46 Conclusions: These results clearly reveal important knowledge on the causal role of MDD in  
47 the risk of type 2 diabetes without a residual confounding, whereas the causality of BPD and  
48 SCZ was not shown. Therefore, careful attention should be paid to MDD patients in type 2  
49 diabetes prevention and treatment.

50

51

## 52 INTRODUCTION

53 To date, many epidemiologic studies have suggested the link between type 2 diabetes  
54 and severe mental illness (SMI) including bipolar disorder (BPD), major depressive disorder  
55 (MDD), and schizophrenia (SCZ) (1). The prevalence of type 2 diabetes among individuals  
56 with SMI has been estimated to be 8% to 17% in BPD, and 16% to 25% in SCZ; further,  
57 depressed adults have a 37% increased risk of developing type 2 diabetes (2-4). The side effects  
58 of the medication used for treating SMI, unhealthy lifestyle behaviors of patients with SMI,  
59 and hypothalamic-pituitary-adrenal (HPA) axis dysregulation could contribute to the  
60 association of SMI with type 2 diabetes (5; 6). For instance, medications such as antipsychotics,  
61 antidepressants, and mood stabilizers are likely to contribute to type 2 diabetes development  
62 by leading to insulin resistance or weight gain (1). Moreover, low physical activity, poor diet,  
63 smoking, alcohol, and substance abuse in individuals with SMI might lead to type 2 diabetes  
64 (7).

65 In contrast, type 2 diabetes also affects mental health. One meta-analysis indicated that  
66 the risk of MDD increases in people with type 2 diabetes (8), and a prospective population-  
67 based study showed that the prevalence of schizophrenia was significantly higher in patients  
68 with type 2 diabetes than in the general population (9). Further, a cross-sectional study reported  
69 that type 2 diabetes and prediabetes may be risk factors in patients with BPD (10). Large  
70 longitudinal studies have also demonstrated that type 2 diabetes impacts mental health  
71 negatively (11). As the results of epidemiological studies are inconsistent, the true causality  
72 between SMI and type 2 diabetes is still unclear with potential biases and confounding factors.  
73 Moreover, the difference between the onset age of type 2 diabetes and SMI makes it very  
74 challenging to infer a causal relationship. In general, type 2 diabetes affects middle-aged adults  
75 (after age 40) with low heritability (10–15%), while SMI usually occurs in young adulthood  
76 (in the 20–30s) with high heritability (80–85% for BPD, 80% for SCZ, and 31–42% for MDD)

77 (12; 13). Accordingly, we hypothesized that SMI would precede type 2 diabetes, if there is a  
78 causal effect between them.

79 Therefore, well-designed, two-sample Mendelian randomization (MR) studies, which  
80 have widely been adopted using genetic variants such as single nucleotide polymorphisms  
81 (SNP) for instrumental variable (IV) analysis are needed to pinpoint the causal relationship  
82 between SMI and type 2 diabetes (14). Compared to a one-sample MR, two-sample MR will  
83 not lead to inflated type 1 error rate and false-positive findings. To the best of our knowledge,  
84 a two-sample MR analysis focusing on SMI and type 2 diabetes is currently lacking. For this  
85 purpose, robustness against potential confounders in MR analysis can be achieved if the three  
86 core assumptions for IV, including strong association with intermediate exposure,  
87 independence with confounders, and no direct path for the outcome are satisfied. We  
88 considered several MR approaches including an inverse-variance weighted (IVW) method and  
89 sensitivity analyses—MR-Egger, MR-Egger with a simulation extrapolation (SIMEX),  
90 weighted median approach, and MR-Pleiotropy RESidual Sum and Outlier (MR-PRESSO)  
91 method—in the case of violation of the assumptions (15).

92 Here, we investigate the causality between SMI and type 2 diabetes using genome-  
93 wide summary statistics in a meta-analysis of a large population of European individuals  
94 through two-sample MR study.

95

## 96 **RESEARCH DESIGN AND METHODS**

### 97 **Exposure dataset: summary statistics of genetic association analyses with bipolar** 98 **disorder**

99 SNPs-BPD associations were obtained from 20,352 cases and 31,358 controls who  
100 lived in 14 countries in Europe, North America, and Australia (16). Cases were required to

101 meet international consensus criteria (diagnostic and statistical manual of mental disorders  
102 (DSM-IV), international classification of diseases (ICD)-9, or ICD-10) for a lifetime diagnosis  
103 of BPD established using structured diagnostic instruments from assessments by trained  
104 interviewers, clinician-administered checklists, or medical record reviews. A total of 9,372,253  
105 SNPs were used for genome-wide association (GWA) analyses; among these, 16 genome-wide  
106 significant ( $P < 5 \times 10^{-08}$ ) SNPs associated with BPD were identified after linkage  
107 disequilibrium (LD) pruning (distance  $< 10,000$  kb or LD  $r^2 < 0.001$ ). After removal of SNPs  
108 nominally associated with type 2 diabetes ( $P < 0.05$ ), 11 BPD-associated SNPs were available.

109

110 **Exposure dataset: summary statistics of genetic association analyses with major**  
111 **depressive disorder**

112 The summary statistics for association between SNPs-MDD were obtained through  
113 large-scale genome-wide association meta-analyses of 807,553 individuals (246,363 cases and  
114 561,190 controls) from the UK Biobank, 23andMe, Inc., and psychiatric genomics consortium  
115 (PGC) (17). The definition of MDD was different in each cohort. In the UK Biobank, three  
116 MDD phenotypes were used; 1) self-reported help-seeking for problems with nerves, anxiety,  
117 tension, or depression, 2) self-reported depressive symptoms, and 3) MDD identified from  
118 hospital admission records. In case of 23andMe, Inc., a self-reported clinical diagnosis of  
119 depression was used. Finally, cases were required to meet international consensus criteria  
120 (DSM-IV, ICD-9, or ICD-10) in PGC. A total of 8,098,588 SNPs were combined for meta-  
121 analysis and 50 SNPs were selected as candidates of IVs. None of them were in the same LD  
122 block ( $r^2 < 0.001$ ) or within 10,000 kb of an established signal. We checked the pleiotropic  
123 effect of those SNPs, and eight SNPs associated with type 2 diabetes ( $P < 0.05$ ) were eliminated.  
124 Thus, 42 MDD-associated SNPs were used for our analyses.

125

126 **Exposure dataset: summary statistics of genetic association analyses with schizophrenia**

127 SNPs-SCZ associations were obtained from 33,640 cases and 43,456 controls from the  
128 PGC (18). Cases with clinical diagnosis (not self-report) of SCZ or schizoaffective disorder  
129 were included in our study. Summary statistics of GWA analyses for 13,942,226 SNPs were  
130 available, and 83 variants that were genome-wide significantly associated with schizophrenia  
131 were significant after LD pruning (distance < 10,000 kb or LD  $r^2 < 0.001$ ). Eleven SNPs were  
132 associated with type 2 diabetes ( $P < 0.05$ ), and the remaining 72 SCZ-associated SNPs were  
133 used for our MR analyses.

134

135 **Outcome dataset: summary statistics of genetic association analyses with type-2 diabetes**

136 We obtained summary statistics for associations between SNPs-type 2 diabetes from  
137 the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium stage 1 meta-  
138 analyses with 26,676 cases and 132,532 controls (19). Type 2 diabetes diagnosis was based on  
139 diagnostic fasting glucose ( $\geq 7$  mmol/L) or HbA1c levels ( $\geq 6.5\%$ ), hospital discharge  
140 diagnosis, use of oral diabetes medication, or self-report. Summary statistics of GWA analyses  
141 for 12.1 million SNPs were available and were considered for our MR analyses.

142

143 **Mendelian randomization analysis**

144 All SNPs associated with BPD, MDD, or SCZ were selected separately as candidates  
145 of IVs that had genome-wide significance and were not in a LD block ( $r^2 < 0.001$ ) or within  
146 10000 kb of an established signal.  $F$ -statistics provided an indication of instrument strength  
147 and  $F > 10$  indicated that the analysis was unlikely to suffer from weak instrument bias (20). A  
148 degree of violation of the “NO Measurement Error” (NOME) assumption was quantified using  
149  $I^2$  statistics and  $I^2 > 90$  indicated lesser dilution of the estimates in MR analysis (21). For the  
150 detection of pleiotropic outlier SNPs, Cochran’s Q-test in the inverse-variance weighted (IVW)

151 method and Rucker Q' statistics in the MR-Egger were used (22). We further conducted an  
152 MR-Pleiotropy RESidual Sum and Outlier (MR-PRESSO) test as an indicator of no violations  
153 of MR assumptions in the final IV sets (23). Given that no weak instrument bias ( $F > 10$ ) was  
154 observed and the three tests (Cochran's Q-test, Rucker Q' test, and MR-PRESSO test) indicated  
155 no directional pleiotropic bias, the IVW method was applied, which is robust when all SNPs  
156 are valid instruments (15). Here "valid" means that the following three conditions are satisfied:  
157 (i) IVs are strongly associated with exposure, (ii) IVs independent of confounders, and (iii) IVs  
158 do not affect the outcome directly. If we assume instruments-outcome association and  
159 exposure-outcome association are denoted by  $\beta_{GY}$  and  $\beta_{XY}$ , respectively, then the IVW  
160 estimate of causal effect (i.e., effect of the exposure on the outcome) can be obtained from the  
161 inverse-variance weighted mean of ratio estimates ( $\beta_{GY}/\beta_{XY}$ ). If the pleiotropy and outlier SNPs  
162 were detected from MR-PRESSO, IVW is not recommended, and we consider several  
163 sensitivity analyses to minimize bias. Weighted median method provides valid causal estimates  
164 unless more than 50% of the instruments are invalid (15). MR-Egger method can estimate  
165 appropriate causal effects in the presence of pleiotropy effects even if all SNPs are invalid (15).  
166 When Cochran's Q-test is rejected or both Cochran's Q and Rucker Q' tests are rejected, the  
167 MR-Egger method is recommended (15). If the measurement error of the instruments is large  
168 ( $I^2 > 90$ ), the method of SIMEX was applied to correct attenuation bias (21). Furthermore, we  
169 conducted a bi-directional MR to investigate the presence of reverse-causality between SMI  
170 and type 2 diabetes. The Šidák correction for multiple comparisons was used for analysis and  
171 thus, threshold of  $P$  of  $1-(1-0.05)^{\frac{1}{3}} = 0.017$  (24). Observed power (or post-hoc power)  
172 calculations were performed using the online tool (<https://sb452.shinyapps.io/power/>) (25).  
173 The proportion of variance in the exposure explained by the genetic variants ( $R^2$ ) were required  
174 for MR power analysis, and 0.23 (BPD), 0.089 (MDD), 0.24 (SCZ), and 0.196 (type 2 diabetes)  
175 were used.

## 176 RESULTS

### 177 Effect of bipolar disorder on type 2 diabetes

178 Eleven SNPs that genome-wide significantly associated with BPD but not type 2  
179 diabetes were used as instrument variables. All SNP-exposure and SNP-outcome effects are  
180 presented in Supplementary Table 1. We found no evidence of weak instrument bias ( $F$ -statistic  
181 = 32.9), and heterogeneity and outlier pleiotropy were not observed (Q-test,  $P = 0.718$ ; Q'-test,  
182  $P = 0.821$ ; MR-PRESSO global test,  $P = 0.695$ ) (Table 1). The MR-Egger test also indicated  
183 no directional pleiotropic bias (intercept  $P = 0.165$ ) and there was no violation of the NOME  
184 assumption ( $I^2 = 96.9\%$ ) (Table 1). Since all IV assumptions were satisfied, the IVW method  
185 was considered to be the most appropriate to provide unbiased estimate (15; 22). IVW showed  
186 non-significant effect on the type 2 diabetes (odds ratio (OR): 1.006, 95% CI: 0.918–1.104,  $P$   
187 = 0.892). The post-hoc statistical power estimated using OR was 2.5%. Non-significant results  
188 were also obtained from other sensitivity analyses (MR-Egger, OR: 0.681, 95% CI: 0.389–  
189 1.191,  $P = 0.178$ ; MR-Egger (SIMEX), OR: 0.995, 95% CI: 0.908–1.089,  $P = 0.917$ ; weighted  
190 median, OR: 0.982, 95% CI: 0.868–1.111,  $P = 0.770$ ) (Table 2). We checked the reverse-causal  
191 association between BPD and type 2 diabetes with the 35 SNPs associated with type 2 diabetes.  
192 There was no weak instrument bias ( $F$ -statistic = 35.8) and no violation of the NOME  
193 assumption ( $I^2 = 97.3\%$ ). No evidence of heterogeneity was found from the Q-test ( $P = 0.684$ ),  
194 Q'-test ( $P = 0.639$ ), and MR-PRESSO global test ( $P = 0.598$ ) (Table 1). Non-significant  
195 reverse-causal effect was found (IVW, OR: 1.031, 95% CI: 0.971–1.095,  $P = 0.313$ ; MR-Egger,  
196 OR: 1.051, 95% CI: 0.793–1.394,  $P = 0.727$ ; MR-Egger (SIMEX), OR: 0.993, 95% CI: 0.909–  
197 1.083,  $P = 0.867$ ; weighted median OR: 1.041, 95% CI: 0.956–1.134,  $P = 0.349$ ) (Table 3).  
198 The associations of the variants with BPD and type 2 diabetes are shown in a scatter plot with  
199 four MR-fitted lines (Figure 1A).



## 201 **Effect of major depressive disorder on type 2 diabetes**

202           Forty-two independent SNPs that associated with MDD but not type 2 diabetes were  
203 used as IVs. All SNP-exposure and SNP-outcome effects are presented in Supplementary Table  
204 2. Weak instrument assumption was guaranteed by  $F$ -statistic (37.9) and there was no  
205 measurement error of estimates from the MR study ( $I^2 = 97.3\%$ ). No evidence of heterogeneity  
206 or pleiotropy was confirmed through the Q-test ( $P = 0.808$ ), Q'-test ( $P = 0.788$ ), and MR-  
207 PRESSO global test ( $P = 0.733$ ) (Table 1). Since all IV assumptions were satisfied, the IVW  
208 method was chosen and showed significant results (OR: 1.191, 95% CI: 1.036–1.372,  $P =$   
209 0.014). The post-hoc statistical power estimated from the ORs was 100%. Among the other  
210 sensitivity analyses, MR-Egger (SIMEX) showed a consistent significant result (OR: 1.162,  
211 95% CI: 1.024–1.318,  $P = 0.025$ ) and weighted median showed a nominally significant ( $P <$   
212 0.1) result (OR: 1.196, 95% CI: 0.984–1.453,  $P = 0.072$ ). Non-significant result of MR-Egger  
213 may be attributable to the low power of ME-Egger (OR: 0.934, 95% CI: 0.402–2.172,  $P =$   
214 0.875) (Table 2). To check the reverse-causal effect, 39 variants were used as instruments. We  
215 found that all assumptions for MR analyses were preserved ( $F$ -statistic = 36.0; Q-test,  $P =$   
216 0.714; Q'-test,  $P = 0.683$ ; MR-PRESSO global test,  $P = 0.711$ ;  $I^2 = 97.3\%$ ) (Table 1). Non-  
217 significant reverse-causal effect was found (IVW, OR: 1.002, 95% CI: 0.985–1.020,  $P = 0.793$ ;  
218 MR-Egger, OR: 1.008, 95% CI: 0.949–1.070,  $P = 0.798$ ; MR-Egger (SIMEX), OR: 1.002, 95%  
219 CI: 0.985–1.019,  $P = 0.808$ ; weighted median, OR: 1.007, 95% CI: 0.982–1.134,  $P = 0.581$ )  
220 (Table 3). The associations of the variants with MDD and type 2 diabetes are shown in a scatter  
221 plot with four MR-fitted lines (Figure 1B).

222

## 223 **Effect of schizophrenia on type 2 diabetes**

224           Seventy-two independent SNPs that associated with SCZ, but not type 2 diabetes were  
225 found to have strong instrument strength ( $F$ -statistic = 41.5) and non-significant heterogeneity

226 and outlier pleiotropy (Q-test,  $P = 0.319$ ; Q'-test,  $P = 0.290$ ; MR-PRESSO global test,  $P =$   
227  $0.704$ ) (Table 1). All SNP-exposure and SNP-outcome effects are presented in Supplementary  
228 Table 3. In addition, there was no dilution bias from violation of the NOME assumption ( $I^2 =$   
229  $97.2\%$ ). The IVW method was the most powerful and showed a non-significant result (OR:  
230  $1.016$ , 95% CI:  $0.974$ – $1.059$ ,  $P = 0.463$ ). The post-hoc statistical power by estimated ORs was  
231  $10.9\%$ . The other sensitivity analyses results showed a non-significant effect of SCZ on type 2  
232 diabetes (MR-Egger, OR:  $1.012$ , 95% CI:  $0.851$ – $1.204$ ,  $P = 0.888$ ; MR-Egger (SIMEX), OR:  
233  $1.015$ , 95% CI:  $0.981$ – $1.060$ ,  $P = 0.511$ ; weighted median, OR:  $1.016$ , 95% CI:  $0.955$ – $1.081$ ,  
234  $P = 0.615$ ) (Table 2). To detect reverse-causal effect, forty-three SNPs were used as instruments.  
235  $F$ -statistic showed no weak instrument bias ( $F$ -statistic =  $35.8$ ) and no violation of the NOME  
236 assumption ( $I^2 = 97.2$ ) (Table 1). Heterogeneity test showed substantial evidence of outlier  
237 pleiotropy using the Q-test ( $P < 0.001$ ), Q'-test ( $P < 0.001$ ), and MR-PRESSO global test ( $P <$   
238  $0.001$ ) (Table 1). Since all three tests were rejected, the MR-PRESSO method was adopted (15)  
239 after excluding the two outlier SNPs (OR:  $0.999$ , 95% CI:  $0.991$ – $1.009$ ,  $P = 0.987$ ), suggesting  
240 non-significant effect of type 2 diabetes on SCZ. The associations of the variants with SCZ and  
241 type 2 diabetes are shown in a scatter plot with four MR-fitted lines (Figure 1C).

242

## 243 CONCLUSIONS

244 In the present study, two-sample MR results provided solid evidence in support of the  
245 hypothesis that MDD increases the risk of type 2 diabetes, whereas BPD and SCZ were not  
246 identified as risk factors for type 2 diabetes. Bi-directional MR study also confirmed that there  
247 was no reverse-causality between SMI and type 2 diabetes, and the asymmetry in the effects  
248 of the instruments on type 2 diabetes and MDD supports the fact that MDD is one of the causal  
249 factors that influences type 2 diabetes. However, causal effects of MDD on type 2 diabetes  
250 development have been demonstrated to be controversial in observational studies. One

251 systematic review demonstrated that MDD is associated with a 60% increased risk of type 2  
252 diabetes, while the evidence is also compatible with the high prevalence rates of MDD among  
253 individuals with type 2 diabetes (27). A large meta-analysis showed that type 2 diabetes is  
254 associated with only a modestly increased risk of MDD (28). MDD is difficult to detect in older  
255 adults which may partially explain why this association was so modest (29).

256 Our finding, the causal role of MDD in increased risk of type 2 diabetes, could be  
257 explained by the pathophysiological mechanisms underlying the two diseases. Two major  
258 molecular mechanisms have been suggested to explain the causal pathway between them. First,  
259 the HPA axis, a central stress response system is commonly activated in MDD patients  
260 suffering from emotional stressors, leading to a rise in the levels of glucocorticoids, primarily  
261 cortisol (30). High cortisol level induces and aggravates insulin resistance in a vicious cycle,  
262 such as increased  $\beta$ -cell function and increased insulin release to glucose challenge by  
263 exacerbating progression to insulin resistance (31). Second, the sympathetic nervous system  
264 (SNS) activity is also elevated in MDD (32). The SNS axis interacts complexly with the HPA  
265 axis to maintain homeostasis during stress, resulting in an increased release of cortisol and  
266 other glucocorticoids, catecholamines, growth hormone, and glucagon. Indeed, the  
267 catecholamines have marked metabolic effects, particularly on glucose metabolism (33).

268 However, our findings are inconsistent with some observational study suggesting a  
269 causal role of BPD and SCZ in the risk of type 2 diabetes and that type 2 diabetes predicts the  
270 development of MDD (3). Such associations may have been driven by residual confounding,  
271 because many aspects of the relationship between SMI and type 2 diabetes are yet to be  
272 examined in a controlled manner, and there are many suggestive evidences that can act as  
273 confounders. First, sedentary lifestyle and low physical activity, which have been demonstrated  
274 to be strongly associated with SMI, may play a role as a potential confounder (1). A large meta-  
275 analysis of general population studies reported that sedentary behavior is independently

276 associated with an increased risk of type 2 diabetes (34). In addition, side effects of medication  
277 could also be another important potential confounder. A systematic review of cross-sectional  
278 and prospective studies of psychotropic medications and physical diseases indicated that the  
279 use of antipsychotics, antidepressants, and mood stabilizers can contribute to an increased BMI  
280 which is a major risk factor for type 2 diabetes (35). Especially, antipsychotics, such as  
281 clozapine and olanzapine; antidepressants, such as paroxetine; and mood stabilizers, such as  
282 lithium and valproate have been associated with increasing obesity. Further, the prevalence of  
283 smoking behaviors (daily smoking) was the highest in SCZ, followed by BPD and MDD  
284 compared with the general population and the association with smoking is very strong in SCZ  
285 and BPD, while it is less strong in MDD (36). The evidence that nicotine addiction begins  
286 before any of these SMIs develop suggests that there are shared genes associated with nicotine  
287 addiction and SMI (37).

288 MR studies on the association between SMI and type 2 diabetes are scarce, with no  
289 studies on BPD with type 2 diabetes. To investigate the potential causal relationship of type 2  
290 diabetes with MDD, MR analysis was performed with a large longitudinal cohort from 2011 to  
291 2013 in China (38). Genetic risk scores for type 2 diabetes were chosen as the instruments and  
292 two-stage multiple regression was used for statistical analysis. The results provided evidence  
293 of a potential causal effect of type 2 diabetes on MDD, which is the opposite of our results. We  
294 thought that there is a finite-sample bias in the existing research, because in a one-sample  
295 setting, the fitted values from the first-stage regression are correlated with the outcome in finite  
296 samples even in the absence of a causal effect (39). Regarding the MR studies of SCZ and type  
297 2 diabetes, two-sample MR was performed using the IVW and MR-Egger methods in  
298 Europeans, East Asians, and trans-ancestry groups (40). No evidence of a causal role of type 2  
299 diabetes for SCZ was observed in any of the analyses, which is consistent with our findings;  
300 however, they did not perform bi-directional analysis for causal effect of SCZ on type 2

301 diabetes. Unlike epidemiological studies, the previous and the present MR studies could not  
302 consider multi-episode status of disease, which may have led to non-significant results of SCZ  
303 and BPD. This could be because multi-episode (versus first-episode) persons with SMI were  
304 significantly more likely to have type 2 diabetes than matched controls in the meta-analysis of  
305 observational studies (1).

306         Several limitations of our study need to be acknowledged. First, there are different  
307 clinical subtypes of MDD (melancholic, psychotic, atypical, or undifferentiated) and bipolar  
308 disorder (type 1 or 2) and mood states (manic, depressive, mixed, or euthymic); however, a  
309 large category of diseases was analyzed without distinction. Second, although we conducted  
310 bi-directional MR studies, the sample size of GWA studies for instruments and BPD/SCZ (less  
311 than 100,000) was relatively small, which could lead to low power of the analysis. Third, we  
312 only included European population; hence, it is difficult to apply the same clinical  
313 interpretation to other races. Nevertheless, the present study has implications in that the well-  
314 designed, two-sample MR study for SMI and type 2 diabetes produced less biased results than  
315 those of the existing epidemiological studies or one-sample MR study. In addition, the present  
316 study clearly showed the causality of MDD on type 2 diabetes, which is supported by  
317 previously reported underlying biological mechanisms. Therefore, it is imperative to consider  
318 screening for diabetes and metabolic abnormalities in patients with MDD or probable MDD.

319

## 320 **ACKNOWLEDGEMENTS**

321 This work was supported by the Industrial Core Technology Development Program  
322 (20000134) funded by the Ministry of Trade, Industry and Energy (MOTIE, Korea), and the  
323 National Research Foundation of Korea (2017M3A9F3046543). The authors declare that the

324 research was conducted in the absence of any commercial or financial relationships that could  
325 be construed as a potential conflict of interest.

326

## 327 **AUTHOR CONTRIBUTIONS**

328 H.J. analyzed and interpreted the results and wrote the manuscript. J.L and S.O contributed to  
329 discussion. S.W. and S.L. designed the study. All authors revised this paper critically for  
330 important intellectual content.

331

332

333

334

335

336

337

338

339

340

341

342

343

344

## 345 REFERENCES

- 346 1. Vancampfort D, Correll CU, Galling B, Probst M, De Hert M, Ward PB, Rosenbaum S,  
347 Gaughran F, Lally J, Stubbs B. Diabetes mellitus in people with schizophrenia, bipolar disorder  
348 and major depressive disorder: a systematic review and large-scale meta-analysis. *World*  
349 *Psychiatry* 2016;15:166-174
- 350 2. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, Lehman A.  
351 Prevalence and correlates of diabetes in national schizophrenia samples. *Schizophr Bull*  
352 2000;26:903-912
- 353 3. Regenold WT, Thapar RK, Marano C, Gavirneni S, Kondapavuluru PV. Increased  
354 prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and  
355 schizoaffective disorders independent of psychotropic drug use. *J Affect Disord* 2002;70:19-  
356 26
- 357 4. Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid  
358 depression in adults with diabetes: a meta-analysis. *Diabetes Care* 2001;24:1069-1078
- 359 5. Vancampfort D, Mitchell AJ, De Hert M, Sienaert P, Probst M, Buys R, Stubbs B. Type 2  
360 diabetes in patients with major depressive disorder: a meta-analysis of prevalence estimates  
361 and predictors. *Depress Anxiety* 2015;32:763-773
- 362 6. Enger C, Jones ME, Kryzhanovskaya L, Doherty M, McAfee AT. Risk of developing  
363 diabetes and dyslipidemia among adolescents with bipolar disorder or schizophrenia. *Int J*  
364 *Adolesc Med Health* 2013;25:3-11
- 365 7. Scott D, Happell B. The high prevalence of poor physical health and unhealthy lifestyle  
366 behaviours in individuals with severe mental illness. *Issues Ment Health Nurs* 2011;32:589-  
367 597
- 368 8. Nouwen A, Winkley K, Twisk J, Lloyd CE, Peyrot M, Ismail K, Pouwer F, European  
369 Depression in Diabetes (EDID) Research Consortium. Type 2 diabetes mellitus as a risk factor  
370 for the onset of depression: a systematic review and meta-analysis. *Diabetologia* 2010;53:2480-  
371 2486
- 372 9. Huang CJ, Hsieh HM, Tu HP, Jiang HJ, Wang PW, Lin CH. Schizophrenia in type 2 diabetes  
373 mellitus: prevalence and clinical characteristics. *Eur Psychiatry* 2018;54:102-108
- 374 10. Hajek T, Calkin C, Blagdon R, Slaney C, Alda M. Type 2 diabetes mellitus: a potentially  
375 modifiable risk factor for neurochemical brain changes in bipolar disorders. *Biol Psychiatry*  
376 2015;77:295-303
- 377 11. Feng X, Astell-Burt T. Impact of a type 2 diabetes diagnosis on mental health, quality of  
378 life, and social contacts: a longitudinal study. *BMJ Open Diabetes Res Care* 2017;5: e000198
- 379 12. Consortium IS: Common polygenic variation contributes to risk of schizophrenia that  
380 overlaps with bipolar disorder. *Nature* 2009;460:748-752
- 381 13. Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review  
382 and meta-analysis. *Am J Psychiatry* 2000;157:1552-1562
- 383 14. Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental  
384 variables in Mendelian randomization: comparison of allele score and summarized data  
385 methods. *Stat Med* 2016;35:1880-1906
- 386 15. Jin H, Lee S, Won S. Causal evaluation of laboratory markers in type 2 diabetes on cancer  
387 and vascular diseases using various Mendelian randomization tools. *medRxiv*  
388 2020:2020.08.21.20179622
- 389 16. Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, Mattheisen M, Wang  
390 Y, Coleman JR, Gaspar HA, de Leeuw CA. Genome-wide association study identifies 30 loci  
391 associated with bipolar disorder. *Nat Genet* 2019;51:793-803
- 392 17. Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, Coleman JR,  
393 Hagenaaers SP, Ward J, Wigmore EM, Alloza C. Genome-wide meta-analysis of depression

- 394 identifies 102 independent variants and highlights the importance of the prefrontal brain  
395 regions. *Nat Neurosci* 2019;22:343-352
- 396 18. Lam M, Chen CY, Li Z, Martin AR, Bryois J, Ma X, Gaspar H, Ikeda M, Benyamin B,  
397 Brown BC, Liu R. Comparative genetic architectures of schizophrenia in East Asian and  
398 European populations. *Nat Genet* 2019;51:1670-1678
- 399 19. Scott RA, Scott LJ, Mägi R, Marullo L, Gaulton KJ, Kaakinen M, Pervjakova N, Pers TH,  
400 Johnson AD, Eicher JD, Jackson AU. An expanded genome-wide association study of type 2  
401 diabetes in Europeans. *Diabetes* 2017;66:2888-2902
- 402 20. Burgess S, Thompson SG; CRP CHD Genetics Collaboration. Avoiding bias from weak  
403 instruments in Mendelian randomization studies. *Int J Epidemiol* 2011;40:755-764
- 404 21. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan NA, Thompson JR.  
405 Assessing the suitability of summary data for two-sample Mendelian randomization analyses  
406 using MR-Egger regression: the role of the I<sup>2</sup> statistic. *Int J Epidemiol* 2016;45:1961-1974
- 407 22. Bowden J, Spiller W, Del Greco M F, Sheehan N, Thompson J, Minelli C, Davey Smith G.  
408 Improving the visualization, interpretation and analysis of two-sample summary data  
409 Mendelian randomization via the Radial plot and Radial regression. *Int J Epidemiol*  
410 2018;47:1264-1278
- 411 23. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in  
412 causal relationships inferred from Mendelian randomization between complex traits and  
413 diseases. *Nat Genet* 2018;50:693-698
- 414 24. Šidák Z. Rectangular confidence regions for the means of multivariate normal distributions.  
415 *J Am Stat Assoc* 1967;62:626-633
- 416 25. Burgess S, Smith GD, Davies NM, Dudbridge F, Gill D, Glymour MM, Hartwig FP, Holmes  
417 MV, Minelli C, Relton CL. Guidelines for performing Mendelian randomization investigations.  
418 *Wellcome Open Research* 2020;4:186
- 419 26. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments:  
420 effect estimation and bias detection through Egger regression. *Int J Epidemiol* 2015;44:512-  
421 525
- 422 27. Lustman PJ, Griffith LS, Clouse RE, Cryer PE. Psychiatric illness in diabetes mellitus.  
423 Relationship to symptoms and glucose control. *J Nerv Ment Dis* 1986; 174:736-742
- 424 28. Mezuk B, Eaton WW, Albrecht S, Golden SH. Depression and type 2 diabetes over the  
425 lifespan: a meta-analysis. *Diabetes Care* 2008;31:2383-2390
- 426 29. Gallo JJ, Anthony JC, Muthén BO. Age differences in the symptoms of depression: a latent  
427 trait analysis. *J Gerontol* 1994;49:P251-P264
- 428 30. Tsigos C, Chrousos GP. Hypothalamic–pituitary–adrenal axis, neuroendocrine factors and  
429 stress. *J Psychosom Res* 2002;53:865-871
- 430 31. Geer EB, Islam J, Buettner C. Mechanisms of glucocorticoid-induced insulin resistance:  
431 focus on adipose tissue function and lipid metabolism. *Endocrinol Metab Clin North Am*  
432 2014;43:75-102
- 433 32. Tabák AG, Akbaraly TN, Batty GD, Kivimäki M. Depression and type 2 diabetes: a causal  
434 association? *Lancet Diabetes Endocrinol* 2014;2:236-245
- 435 33. Barth E, Albuszies G, Baumgart K, Matejovic M, Wachter U, Vogt J, Radermacher P, Calzia  
436 E. Glucose metabolism and catecholamines. *Crit Care Med* 2007;35:S508-S518
- 437 34. Biswas A, Oh PI, Faulkner GE, Bajaj RR, Silver MA, Mitchell MS, Alter DA. Sedentary  
438 time and its association with risk for disease incidence, mortality, and hospitalization in adults:  
439 a systematic review and meta-analysis. *Ann Intern Med* 2015;162:123-132
- 440 35. Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants  
441 and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and  
442 bipolar disorder. *World Psychiatry* 2015;14:119-136
- 443 36. Diaz FJ, James D, Botts S, Maw L, Susce MT, De Leon J. Tobacco smoking behaviors in



- 444 bipolar disorder: a comparison of the general population, schizophrenia, and major depression.  
445 Bipolar Disord 2009;11:154-165
- 446 37. Kendler KS, Neale MC, MacLean CJ, Heath AC, Eaves LJ, Kessler RC. Smoking and  
447 major depression. A causal analysis. Arch Gen Psychiatry 1993;50:36-43
- 448 38. Xuan L, Zhao Z, Jia X, Hou Y, Wang T, Li M, Lu J, Xu Y, Chen Y, Qi L, Wang W. Type 2  
449 diabetes is causally associated with depression: a Mendelian randomization analysis. Front  
450 Med 2018;12:678-687
- 451 39. Burgess S, Davies NM, Thompson SG. Bias due to participant overlap in two-sample  
452 Mendelian randomization. Genet Epidemiol 2016;40:597-608
- 453 40. Li Z, Chen P, Chen J, Xu Y, Wang Q, Li X, Li C, He L, Shi Y. Glucose and insulin-related  
454 traits, type 2 diabetes and risk of schizophrenia: a Mendelian randomization study.  
455 EBioMedicine 2018;34:182-188
- 456
- 457
- 458
- 459

460 **Table 1.** Assumption test for instrumental variable sets

No.	Exposure	Outcome	N	F-stat	$I^2$ (%)	Q-test	Q'-test	MR-PRESSO global test
1	BPD	type 2 diabetes	11	32.9	96.9	0.718	0.821	0.695
2	MDD		42	37.9	97.3	0.808	0.788	0.733
3	SCZ		72	41.5	97.6	0.319	0.290	0.704
4	type 2 diabetes	BPD	35	35.8	97.3	0.684	0.639	0.598
5		MDD	39	36.0	97.3	0.714	0.683	0.711
6		SCZ	43	35.8	97.2	<0.001	<0.001	<0.001

461 N = Number of instruments, F-stat = F statistics, Q-test =  $P$ -value for the Q-test from IVW, Q'-test  
462 =  $P$ -value for the Q'-test from MR-Egger, MR-PRESSO global test =  $P$ -value for MR-PRESSO global  
463 test, BPD = bipolar disorder, MDD = major depressive disorder, SCZ = schizophrenia, MR-  
464 PRESSO = MR-Pleiotropy RESidual Sum and Outlier  
465

466 **Table 2.** Mendelian randomization results

MR methods	parameter	N	OR	95% CI	P	Power
1. Effect of BPD on type 2 diabetes						
IVW	Estimate	11	1.006	[0.918, 1.104]	0.892	2.5%
MR-Egger	Intercept		1.039	[0.985, 1.095]	0.165	100%
	Slope		0.681	[0.389, 1.191]	0.178	-
MR-Egger (SIMEX)	Intercept		1.003	[1.010, 1.994]	0.540	2.1%
	Slope		0.995	[0.908, 1.089]	0.917	-
Weighted median	Estimate		0.982	[0.868, 1.111]	0.770	13.8%
MR-PRESSO	Estimate		No outlier		-	-
2. Effect of MDD on type 2 diabetes						
IVW	Estimate	42	1.191	[1.036, 1.372]	0.014	100%
MR-Egger	Intercept		1.007	[0.982, 1.033]	0.566	74%
	Slope		0.934	[0.402, 2.172]	0.875	-
MR-Egger (SIMEX)	Intercept		1.004	[1.000, 1.008]	0.036	100%
	Slope		1.162	[1.024, 1.318]	0.025	-
Weighted median	Estimate		1.196	[0.984, 1.453]	0.072	100%
MR-PRESSO	Estimate		No outlier		-	-
3. Effect of SCZ on type 2 diabetes						
IVW	Estimate	72	1.016	[0.974, 1.059]	0.463	10.9%
MR-Egger	Intercept		1.000	[0.987, 1.014]	0.969	6.5%
	Slope		1.012	[0.851, 1.204]	0.888	-
MR-Egger (SIMEX)	Intercept		1.001	[0.998, 1.004]	0.427	9.6%
	Slope		1.015	[0.981, 1.060]	0.511	-
Weighted median	Estimate		1.016	[0.955, 1.081]	0.615	10.9%
MR-PRESSO	Estimate		No outlier		-	-

467 N = Number of instruments, BPD = bipolar disorder, MDD = major depressive disorder, SCZ  
468 = schizophrenia, MR = Mendelian randomization, IVW = inverse-variance weighted, MR-  
469 PRESSO = MR-Pleiotropy RESidual Sum and Outlier, SIMEX = simulation extrapolation, OR  
470 = odds ratio  
471

472 **Table 3.** Bi-directional Mendelian randomization results

MR methods	parameter	N	OR	95% CI	P	Power
1. Effect of type 2 diabetes on BPD						
IVW	Estimate	35	1.031	[0.971, 1.095]	0.313	18.9%
MR-Egger	Intercept		0.998	[0.974, 1.022]	0.890	52.7%
	Slope		1.051	[0.793, 1.394]	0.727	-
MR-Egger (SIMEX)	Intercept		0.997	[0.989, 1.004]	0.428	2.1%
	Slope		0.993	[0.909, 1.083]	0.867	-
Weighted median	Estimate		1.041	[0.956, 1.134]	0.349	34.3%
MR-PRESSO	Estimate			No outlier	-	-
2. Effect of type 2 diabetes on MDD						
IVW	Estimate	39	1.002	[0.985, 1.020]	0.793	2.2%
MR-Egger	Intercept		0.999	[0.994, 1.005]	0.852	18.6%
	Slope		1.008	[0.949, 1.070]	0.798	-
MR-Egger (SIMEX)	Intercept		1.001	[0.999, 1.002]	0.278	2.2%
	Slope		1.002	[0.985, 1.019]	0.808	-
Weighted median	Estimate		1.007	[0.982, 1.033]	0.581	14%
MR-PRESSO	Estimate			No outlier	-	-
3. Effect of type 2 diabetes on SCZ						
IVW	Estimate	43	1.006	[0.939, 1.075]	0.872	2.2%
MR-Egger	Intercept		0.997	[0.974, 1.019]	0.783	50.1%
	Slope		1.040	[0.806, 1.343]	0.758	-
MR-Egger (SIMEX)	Intercept		1.003	[0.997, 1.009]	0.246	3.3%
	Slope		1.009	[0.941, 1.082]	0.785	-
Weighted median	Estimate		0.980	[0.914, 1.050]	0.564	12.4%
MR-PRESSO	Estimate	41	0.999	[0.991, 1.009]	0.987	1%


473 N = Number of instruments, BPD = bipolar disorder, MDD = major depressive disorder, SCZ  
474 = schizophrenia, MR = Mendelian randomization, IVW = inverse-variance weighted, MR-  
475 PRESSO = MR-Pleiotropy RESidual Sum and Outlier, SIMEX = simulation extrapolation, OR  
476 = odds ratio

## FIGURE LEGEND


**Figure 1.** Scatter plots showing the associations of the genetic variants with psychiatric disorders and type 2 diabetes for different methods of Mendelian randomization. (A) The associations of the variants with BPD and type 2 diabetes. (B) The associations of the variants with MDD and type 2 diabetes. (C) The associations of the variants with SCZ and type 2 diabetes.

Abbreviations: BPD = bipolar disorder, MDD = major depressive disorder, SCZ = schizophrenia, MR = Mendelian randomization, IVW = inverse-variance weighted, SIMEX = simulation extrapolation

(A) BPD-Type 2 diabetes



(B) MDD-Type 2 diabetes



(C) SCZ-Type 2 diabetes

